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How to select a drug for the long-term 
treatment of chronic heart failure 
First-line drugs for the treatment of chronic congestive heart failure should produce immediate 
symptomatic benefit, improve exercise tolerance, and thereby improve the quality of life. They 
should preferentially be active as monotherapy or at least reduce the need for comedication. The 
drugs must be safe and well tolerated by patients and change, in the end, the natural history of 
the disease, so that sudden death will be prevented and life expectancy improves. None of the 
currently available drugs satisfies all these criteria. Diuretics, digitalis, converting-enzyme 
inhibitors, and ibopamine come close to the described ideal. (Au HEART J 1990;120:1572-8.) 
Arie J. Man in ‘t Veld, MD, PhD Rotterdam, The Netherlands 
The question addressed in the title of this article is 
certainly not new and has, in fact, been discussed re- 
peatedly in several leading editorials in recent 
years.lm6 Apparently the subject is still surrounded by 
controversies or new developments, particularly in 
the field of innovations in drug treatment of the dis- 
ease that are required for frequent reorientation. For 
many years digoxin and diuretics were the only 
choices for the treatment of chronic congestive heart 
failure (CHF). However, even the combination of the 
two drugs fails to help patients with advanced disease 
and those who have the most debilitating forms of 
CHF. The efficacy of digoxin for patients with CHF 
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who are in sinus rhythm has been disputed for almost 
200 years.l However, some recently reported, care- 
fully controlled, randomized, double-blind trials have 
now shown beyond any doubt that digoxin relieves 
disability and improves exercise tolerance in CHF, 
thereby ending, to some extent, this long-lasting 
discussion.8-‘2 
It should be clearly noted that most of the infor- 
mation in this article as well as several considerations 
for answering the question of how to choose a drug for 
the treatment of CHF, are from reviews by Packer.5y 6 
These criteria13 for choosing a drug for the treatment 
of CHF will also be applied to the novel, orally active 
inodilator ibopamine in this article. 
DRUGSFORCHFTREATMENT 
During the past 5 years, more new drugs have been 
synthesized and evaluated for the treatment of CHF 
than during the previous 200 years.5 More than 80 
different orally active compounds have been admin- 
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Table I. Oral drugs for the treatment of CHF: Vasodilators 
Venodilators 
Isosorbide dinitrate 
Erythrityl tetranitrate 
Pentaerythritol tetranitrate 
Isosorbide 5-mononitrate 
Molsidomine 
Arterial dilators 
Hydralazine 
Dihydralazine 
Endralszine 
Cadralazine 
Dipyridamole 
Minoxidil 
Ro 12-4713 
Fenoldopam 
Pinacidil 
L-Dopa 
Ibopamine 
Calcium antagonists 
Verapamil 
Nifedipine 
Diltiazem 
Nicardipine 
Nisoldipine 
Isradipine 
Felodipine 
Amlodipine 
Nitrendipine 
Mixed 
Flosequinan 
istered to patients with CHF, and more than 30 ad- 
ditional drugs have been tested by the intravenous 
route. Although some of these new drugs have either 
directly or indirectly multiple actions on the complex 
hemodynamic and neurohumoral derangements in 
heart failure, on the basis of their pharmacodynamic 
actions, they can be classified as follows: (1) vasodi- 
lators (arterial-venous, mixed, including a-adrenore- 
ceptor antagonists and calcium antagonists), (2) 
inotropic agents, (3) o-adrenoreceptor antagonists 
(including @-adrenoreceptor “buffers” or “modula- 
tors”), (4) angiotensin-converting enzyme inhibitors, 
and (5) diuretics. 
Some drugs with a combined vasodilator and ino- 
tropic action are classified as “inodilators” according 
to the concept postulated by Opie.14 Ibopamine, a 
prodrug, which is converted into epinine, is one of 
these inodilators with a combined action on adrener- 
gic and dopaminergic receptors, through which ino- 
tropic and vasodilator effects are mediated.15 Beyond 
this inodilator effect, the drug also has a diuretic and 
natriuretic effect, which is mediated through renal 
dopamine receptors. l6 Most of the different com- 
pounds that have been tested in patients with CHF 
are listed in Tables I through IV. 
Table II. 0ra.l drugs for the treatment of CHF: Neurohu- 
moral modulators 
ACE inhibitors 
Captopril 
Enalapril 
Lisinopril 
Quinapril 
Ramipril 
Cilazapril 
Perindopril 
Zofenopril 
Spirapril 
Benazapril 
Sympathetic inhibitors 
Clonidine 
Methyldopa 
Guanabenz 
Bromocriptine 
Lu-Methyl-p-tyrosine 
Guanethidine 
Ibopamine 
a-Adrenoreceptor blockers 
Phenoxybenzamine 
Prazosin 
Trimazosin 
Terazosin 
Doxazosin 
Bunazosin 
Indoramin 
Urapidil 
&Adrenergic blockers 
More than 30 
*(3-Adrenergic partial agonista 
Xamoterol 
Prenalterol 
Serotonin antagonist 
Ketanserin 
ACE, Angiotensin-converting enzyme. 
CLASSIFICATION OF CHF PATIENTS 
The clinical syndrome of CHF represents an enor- 
mous heterogenous entity. The patient with symp- 
toms may present in an early or relatively late stage 
of the disease. However, early and late are certainly 
not synonymous with mild as opposed to severe, since 
different causes of heart failure (ischemic vs nonis- 
chemic) and different stages of neurohumoral adap- 
tion and cardiac remodeling complicate the picture. 
Furthermore, heart failure with left ventricular hy- 
pertrophy as opposed to left ventricular dilatation 
requires a different approach. Also, abnormalities in 
systolic and diastolic cardiac function should be 
taken into account. Still in most trials, patients are 
classified according to the New York Heart Associa- 
tion (NYHA) classification despite the fact that its 
limitations are widely recognized: (1) The classifica- 
tion does not take into account the cause of heart 
failure or the drugs used at the time of assessment; 
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Table III. Oral drugs for the treatment of CHF: Inotropics Table IV. Oral drugs for the treatment of CHF: Diuretics 
c-AMP independent 
Digoxin 
DPI 201-106 
Taurine 
Carnitine 
Co-enzyme QlO 
(3-adrenoreceptor stimulants 
Ephedrine 
Denopamine 
Pirbuterol 
Salbutamol 
Terbutaline 
Ibopamine 
Dopamine agonists 
Fenoldopam 
Dopa 
Ibopamine 
Phosphodiesterase inhibitors 
Amrinone 
Milrinone 
Enoximone 
Imazodan 
Piroximone 
CI-930 
Ro-13-6438 
OPC-8212 
Theophylline 
Calcium sensitizers 
Sulmazol 
Pimobendan 
Direct 
Thiazides 
Loop of Henle 
Ibopamine 
Indirect 
Aldosterone antagonists 
Table V. Requirements for first-line drugs for the treat- 
ment of CHF, according to Packer 
Rapid relief of symptoms 
Reduce mortality 
Effective as monotherapy 
Safe, well tolerated 
Improve exercise tolerance 
Improve quality of life 
Prevent sudden death 
(arrhythmias) 
Change natural history of 
the disease (reduced 
medication requirement, 
hospitalizations, decline in 
left ventricular function) 
Compliance with 
prescription 
GOALS IN CHF TREATMENT 
c-AMP, Cyclic adenosine monophosphate. 
(2) the lifestyle of the patient is one of the major de- 
terminants of the severity of symptoms; (3) the stage 
and success of compensatory mechanisms are not 
taken into account, and (4) above all, the classifica- 
tion is notoriously subjective.4s”7 Nevertheless, since 
the classification judges the functional status of the 
patient, by definition it correlates well with the 
symptoms of the patient and exercise tolerance. 
Consequently, the patient’s quality of life is fairly 
well related to NYHA status, but it is unrelated to the 
hemodynamic status and is also a poor predictor of 
therapeutic response to drugs or a predictor of 
survival after drug treatment.4y I89 ig Consequently, 
the questions, “who should be treated, how should 
one be treated and when should treatment start?,” 
are still not easy to answer from a pathophysiologic 
point of view. Aside from difficulties in predicting the 
therapeutic outcome in patients with CHF, a low left 
ventricular ejection fraction, high concentrations of 
plasma norepinephrine and vasopressin, low plasma 
sodium concentrations, and recurrent ventricular 
tachycardia indicate a bad prognosis. Obviously 
rapid clinical deterioration is also an alarming 
signala 17-20 
CHF is a chronic, disabling, and killing disease. In 
modern Western society, the admission rate to hos- 
pitals because of the disease has increased more than 
threefold within 15 years.20 It is the most common 
disease in subjects over the age of 65 years. Further- 
more, the disease carries a prognosis often worse than 
cancer: &year survival rates of only 50% for even 
mild cases and l-year survival rates of 40 % to 60 % 
in heart failure after a myocardial infarction under- 
line the malignant character of the disease.20 Given 
the prevalence of CHF-more than 15 million people 
worldwide-the disease also represents a major bur- 
den on health care economics. Because the incidence 
of the disease is also expected to rise in the future as 
a result of the aging of the population and better sur- 
vival is expected after myocardial infarction as a 
consequence of intervention with thrombolytic 
agents, angioplasty, and surgery, the ultimate goal 
will be the prevention of the disease.lg Studies to ex- 
plore this option are currently underway. In the in- 
terim, our goals will be to improve the quality of life 
in our patients by offering therapeutic regimens that 
primarily provide symptomatic relief and improve 
exercise tolerance and that secondarily prolong life 
by preventing sudden death caused by arrhythmias, 
which are still the major cause of death in CHF (Ta- 
ble V). 
Volume 120 
Number 6, Part 2 Drug treatment of CHF 1575 
Table VI. Choosing drug therapy for CHF 
Hydralazine Calcium Phosphodiesterase &Blockers 
Diuretics Digorin Enalapril + nitrates antagonists inhibitors buffers (5Prazosin Ibopamine 
Symptoms + + + ? ? ? ? + + 
(short term) 
Exercise ? + + ? ? ? + ? + 
(medium/long term) 
Mortality ? ? + + ? ? ? ? ? 
(long-term) 
Monotherapy ? ? ? ? ? ? + ? + 
Safe 
Well tolerated 
? ? ? ? ? ? ? + + 
+ + + ? ? ? ? + + 
References are reviewed in Packer.6 
+, Positive effect; ?, questionable or negative effect. 
CHOOSING CHF DRUG THERAPY 
Before a drug is chosen for the treatment of CHF, 
an adequate diagnostic workup should be performed 
for the detection of reversible forms of heart failure 
such as alcohol abuse, the use of cardiodepressant 
drugs in subjects with preexisting symptomless left 
ventricular dysfunction (@blockers, calcium antago- 
nists, and antiarrhythmic agents), reversible (silent) 
ischemia, valvular disease, arterial hypertension, ane- 
mia, myxedema, and thyrotoxicosis. 
When considering the requirements for successful 
drug therapy for CHF as formulated by Packer6 few 
drugs fullfill all criteria (Table V and VI). Diuretics 
not invariably improve exercise tolerance, although 
they do provide short-term relief of symptoms. Their 
effect on mortality is unknown. In the long-run they 
are seldom effective when given as monotherapy, and 
because of metabolic derangements, particularly hy- 
pokalemia, their safety is questionable, although the 
drugs are generally well tolerated by patients. Digoxin 
is effective in controlling short-term symptoms: it 
increases exercise capacity, and in strictly controlled 
trial situations, the drug appears to be surprisingly 
well tolerated. However, the effects on mortality are 
not known and long-term efficacy as monotherapy in 
patients who are in sinus rhythm is still much 
disputed as is its safety because of the proarrhythmic 
activity of the drug. Enalapril was the first drug for 
which there was a positive effect on survival in 
patients with endstage CHF. However, the efficacy of 
the drug as monotherapy in patients with symptoms 
has not been demonstrated. Furthermore, the effects 
of angiotensin-converting enzyme inhibitors on renal 
function are still a cause for concern. Combined 
treatment with hydralazine and nitrates prolongs 
survival in CHF. However, the effects on exercise 
tolerance are disappointing, and short-time symp- 
tomatic benefit is negligible. Although the initial en- 
thusiasm for the hemodyamic profile of the calcium 
antagonists in CHF has provoked widespread re- 
search activities, the negative inotropic actions of the 
drugs, particularly in subjects with the most com- 
promised left ventricular function, have mitigated 
this interest. Finding the right patient for the right 
drug is still one of the problems to be solved. 
Reasoning along similar lines also situates the phos- 
phodiesterase inhibitors for the moment not in the 
position of first-line agents. Selection of the right pa- 
tient is also still a major problem for prescribing @- 
blockers or P-buffers, drugs with partial agonist 
activity. Here again, in subjects with severe left ven- 
tricular dysfunction, the negative inotropic effects of 
these drugs can easily cause rapid deterioration of the 
clinical status of the patient. Of the a-blockers, pra- 
zosin has been investigated extensively. This drug 
reduces preload and afterload, ensures rapid relief of 
symptoms, and has no negative inotropic activity, but 
positive effects on survival could not be demon- 
strated. This is possibly related to the rapid develop- 
ment of tolerance for this drug, which has been 
reported frequently. 
IS THERE A PLACE FOR IBOPAMINE IN CHF 
TREATMENT? 
Chemistry and receptor pharmacology. Ibopamine is 
the 3,4-diisobutyrylester of N-methyldopamine or 
epinine. Esterase activity in the blood rapidly con- 
verts ibopamine into epinine, which is the active 
moiety of the molecule, so that ibopamine can be 
considered a prodrug. Animal studies have shown 
that epinine has dopaminergic and (II- and P-adren- 
ergic activities in cardiac and vascular tissue. These 
activities result in positive inotropic, vasodilating, 
natriuretic, and diuretic effects, which led the origi- 
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nal investigators to study this drug in humans, par- 
ticularly in patients with CHF.21 
The activities of epinine on a host of cardiovascu- 
lar postsynaptic, presynaptic, and ganglionic recep- 
tors do not create an easy understanding of its mech- 
anism of action. Positive inotropic effects can be me- 
diated by @I- and cu-adrenoreceptors, although the 
latter are unlikely to play a role in this respect in hu- 
mans. Vasodilatation may be achieved directly by 
stimulation of postsynaptic DAl- and /?2-adrenore- 
ceptors and indirectly by stimulation of presynaptic 
a2-receptors and DAZ-receptors, which are located on 
ganglionic cells and presynaptically, resulting in a 
reduction in sympathetic vasoconstrictor nerve ac- 
tivity. Natriuresis may result directly from a DAl- 
receptor-mediated mechanism on renal tubular cells 
controlling sodium reabsorption or more indirectly 
by way of a DAs-receptor-mediated mechanism that 
inhibits aldosterone release from the adrenal glands. 
Postsynapticcul- or as-adrenoreceptor activities could 
potentially lead to vasoconstriction, which can, how- 
ever, be offset by the net sum of the above-mentioned 
vasodilator mechanisms. Consequently, ibopamine 
can be listed under several headings in Tables I 
through IV. 
Hemodynamic effects. The acute hemodynamic ef- 
fects of ibopamine have been reviewed recently.22> 23 
In essence flow increases, afterload decreases, and 
arterial pressure and heart rate do not change. Tran- 
sient elevations of cardiac filling pressure have been 
observed at higher dosages of ibopamine (>200 mg). 
The mechanism of this phenomenon is not fully un- 
derstood. Although the initial idea was that it could 
be explained by a-adrenoreceptor-mediated vaso- 
constriction, this hypothesis is not very likely, since 
pretreatment with the cw-adrenoreceptor antagonist 
praxosin does not prevent this response.24 
The neurohumoral counterregulations after an in- 
sult to the myocardium lead to elevated concentra- 
tions of plasma renin, aldosterone, and norepineph- 
rine. After treatment with ibopamine, the elevated 
levels of these neurohumoral parameters de- 
crease.25-28 Thus if one pieces together the profile of 
hemodynamic, renal, and neurohumoral abnormali- 
ties in CHF and the actions of ibopamine on these 
parameters, a mirror image emerges. However, this 
does not necessarily imply long-term clinical efficacy 
of the drug in the areas of improved quality of life or 
survival. 
Efficacy. A review of several noncomparative and 
comparative studies of ibopamine shows that the 
drug maintains its hemodynamic improvements es- 
tablished in single-dose studies without significant 
alteration in blood pressure and heart rate.‘O The 
lack of the development of tolerance was recently re- 
ported in two studies. 2gp 3o Dei Cas et al.2g followed 
the hemodynamic response to ibopamine when given 
on a short-term basis at the beginning of treatment 
and after long-term therapy in 15 patients. Hemody- 
namic responses to ibopamine at 0, 1, 2, 3, 8, and 12 
months of therapy were similar. Reffo et aL30 evalu- 
ated ibopamine after 3 months of treatment in 15 
patients compared with placebo under double-blind 
conditions by means of invasive hemodynamic mon- 
itoring. In both evaluations, ibopamine improved 
hemodynamic response to the same extent before and 
after 3 months of treatment, so that the development 
of tolerance could also not be demonstrated in this 
study. 
The clinical efficacy of ibopamine has been dem- 
onstrated for as long as 1 and 2 years. Both in short- 
and long-term comparative studies, ibopamine, 100 
mg, three times daily, improves disability scores, ex- 
ercise tolerance, and left ventricular function during 
exercise. These initially encouraging data have been 
confirmed in double-blind, placebo-controlled 
studies and in comparative studies with digoxin and 
diuretics. In a relatively short-term study (4 weeks) 
in 58 patients with mild-to-moderate CHF stabilized 
on digoxin and diuretics, in half the patients ibo- 
pamine was substituted for digoxin in a double-blind, 
randomized way. Ibopamine appeared to be as effec- 
tive as digoxin in this study as judged by clinical 
symptom and disability scores, echocardiographic 
parameters, left ventricular function, and exercise 
tolerance as measured by bicycle ergometry.31 
Three large, well-controlled, randomized, and dou- 
ble-blind trials have been reported only in abstract 
form to date.32-34 In a 4-week study, ibopamine, 200 
mg, two times daily, was compared with digoxin and 
placebo in 60 untreated patients with NYHA classes 
I and II. Changes in body weight, peripheral edema, 
fatigue, and dyspnea ratings and patients’ question- 
naire scores were evaluated.32 Body weight decreased 
by 3.5,1.7, and 0.9 kg in the ibopamine, digoxin, and 
placebo groups, respectively. Mean edema scores de- 
creased from 1.9 to 0.1, 1.5 to 0.3, and 1.5 to to 1.0, 
respectively. Total mean patient questionnaire scores 
decreased from 6.2 to 1.1,5.3 to 2.7, and 4.7 to 4.6 in 
the three groups, respectively. In another study of 80 
patients in NYHA classes II and III treated with 
digoxin and diuretics, the subjects were randomly al- 
located to receive placebo or ibopamine, 200 mg, 
three times daily.33 Sixty of these patients were fol- 
lowed up for 4 months and 21 were followed for 6 
months. The last group was also included in an ana- 
lyis of exercise tolerance. The mean exercise time was 
greater for the ibopamine-treated group than for the 
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placebo-treated group at 1, 2, and 6 months (place- 
bo, minus 0.35 minute, and ibopamine, plus 1.02 
minute, p < 0.05). After 6 months of treatment, 70 % 
of ibopamine-treated patients improved compared 
with baseline versus 40% of the patients receiving 
placebo. Improvement in symptom score was greater 
for the ibopamine-treated patients than for placebo- 
treated patients at 1, 2, and 6 months (p < 0.05). In 
a double-blind study of 247 patients in NYHA classes 
I and II, placebo (n = 63), hydrochlorothiaside, 25 
mg, two times daily (n = 60), ibopamine, 200 mg, two 
times daily (n = 61), or ibopamine plus hydrochlo- 
rothiazide (n = 63) were compared for 8 weeks.34*43 
All active treatments were more effective than pla- 
cebo in the reduction of body weight and edema. Pa- 
tients withdrawn from treatment because of insuffi- 
cient therapeutic response included 15 on placebo, 3 
on ibopamine, 2 on ibopamine plus hydrocholothiaz- 
ide, and 2 on hydrochlorothiazide alone. All treat- 
ment groups had a similar incidence of adverse 
events, although there was a greater incidence of hy- 
pokalemia in hydrochlorothiazide-treated patients. 
Although further double-blind, controlled studies 
are required to verify the long-term (more than 12 
months) beneficial effects of ibopamine, it already ap- 
pears that this inodilator is potentially an attractive 
addition to the treatment of CHF as a substi- 
tute for digoxin or diuretics or as an adjunct to these 
remedies either alone or in combination. This sup- 
position was confirmed recently in several larger 
trials.35-38 
Safety and side effects. Noncardiovascular adverse 
effects are mainly from gastrointestinal origin, as 
judged from a large postmarketing survey in Italy in 
515 patients, who were treated for a mean period of 
71/2 months.3g Gastrointestinal symptoms occurred 
in 3.1% of patients, and complaints ranging from 
anxiety to headache, rash, or tremor were between 
0.2% and 0.6%. Because positive inotropic drugs 
may exert arrhythmogenic properties, special atten- 
tion was paid to arrhythmias in patients treated with 
digoxin or ibopamine. Arrhythmia was reported in 
5.6 % of patients receiving ibopamine versus 9.4 % of 
patients receiving digoxin. The issue of potential 
proarrhythmogenic action of ibopamine was further 
addressed in a double-blind, multicenter study of 97 
patients (NYHA classes II and III), who were treated 
with ibopamine, 100 mg, three times daily, for 7 days 
in a random, crossover design with placebo. Any 
complex ventricular arrhythmias under basal condi- 
tions were not present at baseline. While on placebo 
and ibopamine, all patients were subject to 48 hours 
of Holter monitoring. 4o The mean number per hour 
of ectopic supraventricular beats was 26 after ibo- 
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pamine and 22 after placebo (JJ < 0.05). The com- 
plexity of ectopic supraventricular beats did not 
change with the treatment regimen. The mean num- 
ber of ectopic ventricular beats was 31 after ibopam- 
ine and 30 after placebo (p < 0.05). The distribution 
of the patients among the Lown classification in the 
48 hours of ibopamine and placebo was also not dif- 
ferent. None of the patients experienced sustained 
ventricular tachycardia. Ventricular repolarization 
behavior was also not affected. Thus apparently in 
this group of patients, ibopamine appeared to be free 
of proarrhythmogenic activity despite its positive in- 
otropic action. In another study 25 patients (NYHA 
classes II and III) were studied during 7 days of pla- 
cebo, 7 days of ibopamine (100 mg, three times daily) 
and ibopamine (200 mg, three times daily) sequen- 
tially by means of 48 hours of Holter monitoring.41 
No significant differences between the data collected 
under the three conditions were found. Although 
statistically not significant, the number of supraven- 
tricular beats and ventricular premature contrac- 
tions was lower for ibopamine than for placebo. Thus 
it appears that ibopamine is well tolerated by pa- 
tients and is free of proarrhythmic activity. Side ef- 
fects do not limit its prescription in patients with 
symptoms of CHF. 
Survival. Although data from a formal survival trial 
with ibopamine are unavailable today, given that its 
efficacy is comparable with digitalis and diuretics in 
patients with CHF, and considering its excellent tol- 
erability and safety, it is quite likely that there is a 
place for ibopamine as a first-line agent in the treat- 
ment of CHF. Ibopamine could serve as a substitute 
for digitalis or diuretics as monotherapy in NYHA 
classes I and II or as an adjunct to diuretics or dig- 
italis in NYHA classes II and III as a step before 
vasodilator therapy is started. Examination of the 
available published and unpublished reports in which 
survival was a coincidental observation and not the 
primary end point suggests that ibopamine may also 
have a beneficial effect on lifespan in patients with 
moderate or severe heart failure.42 
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